This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cyclacel, Netlist: Early Volume Plays

NEW YORK ( TheStreet) -- A handful of stocks trading near $5 were poised to move on above-average volume during Wednesday's regular session.

Cyclacel Pharmaceuticals (CYCC - Get Report) jumped 12.5% to $2.70 after the company announced that a newly published study in clinical cancer research demonstrates potential for Cyclacel's Seliciclib in treating breast cancer resistant to hormone therapy. Selicicli is currently in phase 2 clinical trials. The 50-day average daily volume for Cyclacel is 7.4 million shares.

Achillion Pharmaceuticals (ACHN - Get Report) rose 4.6% to $2.50 after the company announced additional positive safety and efficacy results from its Phase 2 trial studying elvucitabine in patients infected with HIV. The 50-day average daily volume for Achillion Pharmaceuticals is 893,000 shares.

Netlist (NLST - Get Report) shot up 7.9% to $4.50 after it said it began volume shipments of its non-volatile cache memory product NetVault. The 50-day average daily volume for Netlist is 2.3 million shares.

Sequenom (SQNM - Get Report) edged 0.4% lower to $5.20 after the company announced the launch of its SensiGene fetal sex determination test.The 50-day average daily volume for Sequenom is 3.5 million shares.

-- Reported by Andrea Tse in New York

Check out all of Tuesday's high-volume, under-$10 stocks at the Dollar Store

>>See our new stock quote page.

Follow on Twitter and become a fan on Facebook.
Copyright 2009 Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ACHN $6.32 0.00%
CYCC $0.36 0.00%
NLST $1.23 0.00%
SQNM $1.61 0.00%
AAPL $94.02 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs